FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1972082824> ?p ?o ?g. }

• W1972082824 endingPage "778" @default.
• W1972082824 startingPage "769" @default.
• W1972082824 abstract "To review the available evidence regarding the safety and efficacy of therapies for the treatment of macular edema (ME) associated with central retinal vein occlusion (CRVO).A literature search of the PubMed database was last conducted in March 2014 with no date restrictions but limited to articles published in English. A literature search of the Cochrane Library was also conducted in March 2014 with no date restrictions and without a language limitation. The combined searches yielded 108 citations, of which 20 were deemed clinically relevant for the Ophthalmic Technology Assessment Committee Retina/Vitreous panel to review in full text. Three additional studies were also identified for panel review. The level of evidence of these selected studies was reviewed by the panel methodologist.There were 7 citations representing 4 clinical trials that provided level I evidence supporting the use of anti-vascular endothelial growth factor (VEGF) pharmacotherapies for ME associated with CRVO, including intravitreal ranibizumab (2), aflibercept (3), and bevacizumab (2). There were 3 citations representing 2 studies with level I evidence for intravitreal corticosteroid injection with dexamethasone intravitreal implant (2 citations) or triamcinolone (1 citation), although cataract and glaucoma were observed in these studies. Level I evidence is available on the limited benefit of macular grid-pattern laser photocoagulation (1 citation). Eight other citations reviewed were rated as level II, and 4 citations were rated as level III. Long-term efficacy results (≥2 years of follow-up) are limited to intravitreal ranibizumab at this time, and few studies have evaluated combination therapy with anti-VEGF and corticosteroid versus monotherapy of either class of drug.Level I evidence indicates that intravitreal anti-VEGF pharmacotherapy is safe and effective over 2 years for ME associated with CRVO and that delay in treatment is associated with worse visual outcomes. In addition, level I evidence demonstrates short-term efficacy of intravitreal corticosteroid but also an association with a higher frequency of adverse events." @default.
• W1972082824 created "2016-06-24" @default.
• W1972082824 creator A5006761392 @default.
• W1972082824 creator A5022551584 @default.
• W1972082824 creator A5039903952 @default.
• W1972082824 creator A5062196360 @default.
• W1972082824 creator A5063934250 @default.
• W1972082824 creator A5073166135 @default.
• W1972082824 creator A5073193063 @default.
• W1972082824 date "2015-04-01" @default.
• W1972082824 modified "2023-10-01" @default.
• W1972082824 title "Therapies for Macular Edema Associated with Central Retinal Vein Occlusion" @default.
• W1972082824 cites W1500728559 @default.
• W1972082824 cites W1539571840 @default.
• W1972082824 cites W1565832645 @default.
• W1972082824 cites W1898187276 @default.
• W1972082824 cites W1964672648 @default.
• W1972082824 cites W1968756919 @default.
• W1972082824 cites W1973704949 @default.
• W1972082824 cites W1976775568 @default.
• W1972082824 cites W1978704499 @default.
• W1972082824 cites W1980725734 @default.
• W1972082824 cites W1985498685 @default.
• W1972082824 cites W1986950711 @default.
• W1972082824 cites W1991556117 @default.
• W1972082824 cites W1997262599 @default.
• W1972082824 cites W1999776870 @default.
• W1972082824 cites W2005866783 @default.
• W1972082824 cites W2025804929 @default.
• W1972082824 cites W2026424329 @default.
• W1972082824 cites W2044968030 @default.
• W1972082824 cites W2046018030 @default.
• W1972082824 cites W2052204551 @default.
• W1972082824 cites W2052682546 @default.
• W1972082824 cites W2053282839 @default.
• W1972082824 cites W2057976591 @default.
• W1972082824 cites W2062830058 @default.
• W1972082824 cites W2073973364 @default.
• W1972082824 cites W2075780935 @default.
• W1972082824 cites W2078040311 @default.
• W1972082824 cites W2079974196 @default.
• W1972082824 cites W2082666359 @default.
• W1972082824 cites W2091989599 @default.
• W1972082824 cites W2101608645 @default.
• W1972082824 cites W2103827117 @default.
• W1972082824 cites W2118548020 @default.
• W1972082824 cites W2126501086 @default.
• W1972082824 cites W2128701654 @default.
• W1972082824 cites W2132736166 @default.
• W1972082824 cites W2133950656 @default.
• W1972082824 cites W2144771657 @default.
• W1972082824 cites W2146673937 @default.
• W1972082824 cites W2151081020 @default.
• W1972082824 cites W2159499981 @default.
• W1972082824 cites W2166985747 @default.
• W1972082824 cites W2172223254 @default.
• W1972082824 cites W2324588265 @default.
• W1972082824 cites W57049242 @default.
• W1972082824 doi "https://doi.org/10.1016/j.ophtha.2014.10.013" @default.
• W1972082824 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28551163" @default.
• W1972082824 hasPublicationYear "2015" @default.
• W1972082824 type Work @default.
• W1972082824 sameAs 1972082824 @default.
• W1972082824 citedByCount "70" @default.
• W1972082824 countsByYear W19720828242015 @default.
• W1972082824 countsByYear W19720828242016 @default.
• W1972082824 countsByYear W19720828242017 @default.
• W1972082824 countsByYear W19720828242018 @default.
• W1972082824 countsByYear W19720828242019 @default.
• W1972082824 countsByYear W19720828242020 @default.
• W1972082824 countsByYear W19720828242021 @default.
• W1972082824 countsByYear W19720828242022 @default.
• W1972082824 countsByYear W19720828242023 @default.
• W1972082824 crossrefType "journal-article" @default.
• W1972082824 hasAuthorship W1972082824A5006761392 @default.
• W1972082824 hasAuthorship W1972082824A5022551584 @default.
• W1972082824 hasAuthorship W1972082824A5039903952 @default.
• W1972082824 hasAuthorship W1972082824A5062196360 @default.
• W1972082824 hasAuthorship W1972082824A5063934250 @default.
• W1972082824 hasAuthorship W1972082824A5073166135 @default.
• W1972082824 hasAuthorship W1972082824A5073193063 @default.
• W1972082824 hasConcept C118487528 @default.
• W1972082824 hasConcept C141071460 @default.
• W1972082824 hasConcept C168563851 @default.
• W1972082824 hasConcept C2776478404 @default.
• W1972082824 hasConcept C2776694085 @default.
• W1972082824 hasConcept C2777802072 @default.
• W1972082824 hasConcept C2778257484 @default.
• W1972082824 hasConcept C2778749236 @default.
• W1972082824 hasConcept C2778844676 @default.
• W1972082824 hasConcept C2778903070 @default.
• W1972082824 hasConcept C2780261187 @default.
• W1972082824 hasConcept C2780347916 @default.
• W1972082824 hasConcept C2781100027 @default.
• W1972082824 hasConcept C71924100 @default.
• W1972082824 hasConceptScore W1972082824C118487528 @default.
• W1972082824 hasConceptScore W1972082824C141071460 @default.
• W1972082824 hasConceptScore W1972082824C168563851 @default.

• next